Nevertheless, since the Rho-ROCK pathway is activated in obesity and its inhibition ameliorates various metabolic derangements in obesity [30–32], pharmacological inhibition of this receptor may provide a therapeutic strategy for obesity-related disorders. Here, RHO is linked to obesity due to melanocortin 4 receptor deficiency.